Multisystem inflammatory syndrome in children (MIS-C) is a rare but potentially serious condition that occurs in children and adolescents after COVID-19 infection. The specific clinical picture is determined by significant inflammation affecting multiple body systems, including the cardiovascular, gastrointestinal, and immune systems. MIS-C is often characterized by high fever, abdominal pain, skin rashes, and cardiac and other organ dysfunction. Importantly, this syndrome can develop even several weeks after the acute phase of COVID-19, making it particularly difficult to diagnose and manage. A comprehensive approach to diagnosing and treating MIS-C involves a multidisciplinary team of healthcare professionals and often requires hospitalization.
History of the disease and interesting historical facts
MIS-C syndrome was first described in 2020, when doctors in the UK and Italy began noticing cases of severe inflammatory reactions in children, accompanied by symptoms similar to other inflammatory diseases such as Kawasaki disease. The syndrome was initially associated with COVID-19, but over time, its specific mechanisms and pathogenesis became more apparent. Interestingly, doctors had already encountered similar conditions in the late 19th century and up until the early 20th century, but they were not clearly classified until the discovery of SARS-CoV-2. In 2021, the World Health Organization (WHO) officially recognized MIS-C as a separate condition and recommended its inclusion in international disease classifications.
Epidemiology
According to epidemiological studies, the occurrence of MIS-C has increased significantly since the COVID-19 outbreak. Between March 2020 and December 2021, more than 3,000 cases of MIS-C were reported in the United States, with the highest incidence among children aged 5 to 14 years. Statistics indicate a higher incidence among black and Hispanic children. The incidence rate is approximately 2-5 cases per 100,000 children following COVID-19, but the exact numbers vary by region and time period.
Genetic predisposition to this disease
Research suggests that certain genetic mutations may increase susceptibility to MIS-C in children. In particular, associations have been found with polymorphisms in genes involved in immune response, such as IL-6, IL-10, and TNF-alpha. Hereditary factors associated with immune dysfunction may also play a role in the development of this syndrome. However, despite early research, the genetic predisposition to MIS-C is not fully understood, and further genomic studies are needed to better understand these mechanisms.
Risk factors for the development of this disease
Risk factors for developing MIS-C may include:
- The COVID-19 infection that has been suffered is usually in a severe form.
- Existing immune system problems, such as autoimmune diseases or immunodeficiencies.
- Age - most often the disease is diagnosed in older children.
- Family history of a disease associated with autoimmune reactions or inflammation.
- Racial and ethnic factors, as certain groups have an increased risk of developing the syndrome.
Understanding these risk factors is essential for its prevention and early detection.
Diagnosis of this disease
MIS-C diagnostics includes several key steps:
- Main symptoms: fever, sweating, fatigue, abdominal pain, skin rash, conjunctivitis.
- Laboratory tests: general blood test, presence of inflammation markers (C-reactive protein, procalcitonin), analysis for the presence of the SARS-CoV-2 virus.
- Radiological examinations: ultrasound examination of the heart to assess myocardial function, computed tomography of abdominal organs if indicated.
- Other types of diagnostics: analysis for antibodies to the virus, rheumatological examinations, and, if necessary, tissue biopsy.
- Differential diagnosis: It is necessary to differentiate MIS-C from other infectious and inflammatory diseases such as Kawasaki disease, systemic lupus erythematosus, etc.
The importance of early diagnosis is that timely intervention can significantly reduce the risk of complications.
Treatment
Treatment for MIS-C includes:
- General treatment: hospitalization for monitoring the condition, supportive therapy (fluids, electrolytes).
- Pharmacological treatment: corticosteroids to reduce inflammation, immunoglobulins to modulate the immune response and anticoagulants in prophylactic doses if there are signs of thrombosis.
- Surgical treatment: may be necessary in critical cases such as the development of cardiogenic shock or acute abdominal syndrome.
- Other types of treatment: In some cases, convalescent plasma and antifibrotic drugs may be used.
Tailoring treatment to the individual needs of the patient plays a key role in successful therapy.
List of medications used to treat this disease
The main medications used to treat MIS-C include:
- Corticosteroids (dexamethasone, prednisolone).
- Immunoglobulins (IVIG).
- Antibacterial drugs to prevent secondary infections.
- Anticoagulants (low molecular weight heparin).
- Immunosuppressants (may be used if standard therapy is ineffective).
The effectiveness of these drugs may vary depending on the individual characteristics of each patient and the severity of the disease.
Disease monitoring
Monitoring of patients with MIS-C includes:
- Control stages: regular vital sign checks, monitoring laboratory tests to assess inflammation levels and organ function.
- Forecast: Most patients make a full recovery, but long-term complications such as cardiomyopathy are possible.
- Complications: the development of cardiovascular and other organ dysfunctions is possible, but more often than not, a more favorable outcome should be expected with early treatment.
The approach to monitoring and treating this condition requires the involvement of a multidisciplinary team of specialists.
Age-related features of the disease
The symptoms of MIS-C may vary depending on the age group. Younger children sometimes have less specific symptoms, such as irritability and refusal to eat. While adolescents often have more pronounced clinical manifestations, including symptoms similar to acute allergic inflammation and severe Kawasaki. This difference in manifestations highlights the need for an individualized approach to diagnosis and treatment depending on the patient's age.
Questions and Answers
- What is multisystem inflammatory syndrome in children? It is a rare but serious inflammatory condition that usually occurs after COVID-19 infection and is characterized by damage to multiple body systems.
- What are the main symptoms of MIS-C? The main symptoms include high fever, rash, abdominal pain, red eyes, and heart problems.
- How is MIS-C diagnosed? Diagnosis uses a combination of blood tests, cardiac ultrasound, and symptom assessment to rule out other conditions.
- What is the treatment for MIS-C? Treatment includes corticosteroids, immunoglobulins, supportive care and possible use of anticoagulants.
- What is the prognosis for MIS-C? The prognosis with early diagnosis and adequate treatment is generally favorable, but complications with the heart and other organs are possible.
